Alterity Therapeutics (ASX:ATH) received positive feedback following a type C meeting with the US Food and Drug Administration (FDA) on its planned third-phase development program for drug candidate ATH434 in multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.
MSA is a progressive neurodegenerative disorder affecting the autonomic nervous system and motor control.
The meeting aims to align with the FDA regarding the readiness to start a phase three pivotal trial in MSA, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments